Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 125 articles: HTML format

Single Articles

April 2024
1. AJABNOOR AM, Parisi R, Zghebi SS, Ashcroft DM, et al
   Oral anticoagulant prescribing among patients with cancer and atrial fibrillation in England, 2009-2019.
   Cancer. 2024;130:1316-1329.
   PubMed     Abstract available
   
   
   March 2024
2. VITA E, Monaca F, Milardi D, Mastrantoni L, et al
   Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer.
   Cancer. 2024 Mar 28. doi: 10.1002/cncr.35293.
   PubMed     Abstract available
   
   
   
3. WISNIVESKY JP, Mudd J, Stone K, Slatore CG, et al
   Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer.
   Cancer. 2024 Mar 21. doi: 10.1002/cncr.35286.
   PubMed     Abstract available
   
   
   
4. CITTOLIN-SANTOS GF, Knapp B, Ganesh B, Gao F, et al
   The changing landscape of small cell lung cancer.
   Cancer. 2024 Mar 12. doi: 10.1002/cncr.35281.
   PubMed     Abstract available
   
   
   
5. NIERENGARTEN MB
   Updated American Cancer Society lung cancer screening guidelines: The new guidelines offer expanded criteria recommended for lung cancer screening based on age, smoking status, and smoking history.
   Cancer. 2024;130:656-657.
   PubMed    
   
   
   
6. WEST HJ, Pennell NA
   Lessons from ADAURA: Can we improve on a positive trial?
   Cancer. 2024;130:659-664.
   PubMed    
   
   
   February 2024
7. TAN AC, Lai GGY, Saw SPL, Chua KLM, et al
   Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
   Cancer. 2024 Feb 29. doi: 10.1002/cncr.35263.
   PubMed     Abstract available
   
   
   
8. MORGENSZTERN D
   The expanding role of circulating tumor DNA in resectable non-small cell lung cancer.
   Cancer. 2024 Feb 29. doi: 10.1002/cncr.35268.
   PubMed    
   
   
   
9. 
   Erratum to "Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study".
   Cancer. 2024 Feb 23. doi: 10.1002/cncr.35165.
   PubMed    
   
   
   
10. NIERENGARTEN MB
    Phase 3 AEGEAN trial results show the benefit of perioperative immunotherapy-based treatment for NSCLC.
    Cancer. 2024;130:495-496.
    PubMed    
    
    
    
11. DESAI A, Smith CJ, Pritchett JC, Leventakos K, et al
    Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC).
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35250.
    PubMed     Abstract available
    
    
    
12. ZHOU Y, Guo T, Liang F, Wang Z, et al
    Cumulative incidence and risk factors of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35242.
    PubMed     Abstract available
    
    
    
13. RUSSELL AM, Pack AP, Bailey SC, Weldon CB, et al
    A local perspective on internal, external, and reflexive biomarker testing processes for lung cancer in an academic medical center.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35240.
    PubMed    
    
    
    January 2024
14. IOCOLANO M, Yegya-Raman N, Friedes C, Wang X, et al
    Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.
    Cancer. 2024 Jan 31. doi: 10.1002/cncr.35230.
    PubMed     Abstract available
    
    
    
15. FLOREZ N, Kaufman RA, Yanez-Sarmiento A, Abioye O, et al
    When the unimaginable happens: Lung cancer diagnosis during pregnancy.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35227.
    PubMed    
    
    
    
16. KRATZER TB, Bandi P, Freedman ND, Smith RA, et al
    Lung cancer statistics, 2023.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35128.
    PubMed     Abstract available
    
    
    
17. ROLFO C, Del Re M, Russo A
    Exploring the epigenetic susceptibility mechanisms of lung cancer through DNA methylation markers.
    Cancer. 2024 Jan 18. doi: 10.1002/cncr.35203.
    PubMed    
    
    
    
18. HONG J, Lee J, Park S, Jung HA, et al
    Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B.
    Cancer. 2024 Jan 2. doi: 10.1002/cncr.35175.
    PubMed     Abstract available
    
    
    
19. MEZA R, Cao P, de Nijs K, Jeon J, et al
    Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: A simulation modeling study.
    Cancer. 2024;130:244-255.
    PubMed     Abstract available
    
    
    December 2023
20. TRAN TN, Lee S, Kim HJ, Lee Y, et al
    Treatment-related cardiovascular events in patients with non-small cell lung cancer: Evidence from real-world data with a competing risks approach.
    Cancer. 2023 Dec 16. doi: 10.1002/cncr.35143.
    PubMed     Abstract available
    
    
    
21. WANG S, Xie T, Li Y, Guo L, et al
    Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
    Cancer. 2023;129:3873-3883.
    PubMed     Abstract available
    
    
    
22. ZHAO X, Yang M, Fan J, Wang M, et al
    Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.
    Cancer. 2023 Dec 6. doi: 10.1002/cncr.35130.
    PubMed     Abstract available
    
    
    
23. 
    Immunotherapy plus stereotactic radiation therapy improves event-free survival in early-stage non-small cell lung cancer.
    Cancer. 2023;129:3680.
    PubMed    
    
    
    November 2023
24. GUAN MC, Ding Q, Ning J, Zhu H, et al
    Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus.
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35111.
    PubMed    
    
    
    
25. LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al
    Reply to "Metformin as a booster or obstacle of immunotherapy in patients with non-small cell lung cancer and diabetes mellitus".
    Cancer. 2023 Nov 21. doi: 10.1002/cncr.35134.
    PubMed    
    
    
    
26. GRIESINGER F, Ramagopalan S, Cheung WY, Wilke T, et al
    Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.
    Cancer. 2023 Nov 7. doi: 10.1002/cncr.35094.
    PubMed     Abstract available
    
    
    
27. LANDY R, Cheung LC, Young CD, Chaturvedi AK, et al
    Absolute lung cancer risk increases among individuals with >15 quit-years: Analyses to inform the update of the American Cancer Society lung cancer screening guidelines.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34758.
    PubMed     Abstract available
    
    
    
28. HENDRICK RE, Smith RA
    Benefit-to-radiation-risk of low-dose computed tomography lung cancer screening.
    Cancer. 2023 Nov 1. doi: 10.1002/cncr.34855.
    PubMed     Abstract available
    
    
    October 2023
29. VAN VEGGEL BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, et al
    A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion-positive non-small cell lung cancer.
    Cancer. 2023 Oct 31. doi: 10.1002/cncr.35090.
    PubMed     Abstract available
    
    
    
30. MAHAR AL, Biggs K, Hansford RL, Derksen S, et al
    Stage IV breast, colorectal, and lung cancer at diagnosis in adults living with intellectual or developmental disabilities: A population-based cross-sectional study.
    Cancer. 2023 Oct 30. doi: 10.1002/cncr.35068.
    PubMed     Abstract available
    
    
    
31. CHOI E, Luo SJ, Ding VY, Wu JT, et al
    Risk model-based management for second primary lung cancer among lung cancer survivors through a validated risk prediction model.
    Cancer. 2023 Oct 25. doi: 10.1002/cncr.35069.
    PubMed     Abstract available
    
    
    
32. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    PubMed     Abstract available
    
    
    
33. FLOREZ N, Kiel L, Meza K, Wei Z, et al
    Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35057.
    PubMed     Abstract available
    
    
    
34. VAN TUIJL LA, Basten M, Pan KY, Vermeulen R, et al
    Depression, anxiety, and the risk of cancer: An individual participant data meta-analysis.
    Cancer. 2023;129:3287-3299.
    PubMed     Abstract available
    
    
    
35. 
    Erratum to "JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer".
    Cancer. 2023 Oct 13. doi: 10.1002/cncr.35064.
    PubMed    
    
    
    
36. TAMMEMAGI MC, Cina K, Kitts AKB, Koop D, et al
    Sensitivity of US Preventive Services Task Force and PLCOm2012 lung cancer screening eligibility criteria in individuals with lung cancer in South Dakota self-reporting as Indigenous and non-Indigenous.
    Cancer. 2023 Oct 9. doi: 10.1002/cncr.34947.
    PubMed     Abstract available
    
    
    
37. NIERENGARTEN MB
    Stopping immunotherapy after 2 years is practical in patients with advanced non-small cell lung cancer.
    Cancer. 2023;129:2925-2926.
    PubMed    
    
    
    September 2023
38. PINSKY PF, Osarogiagbon R
    Diagnostic follow-up of indeterminate pulmonary nodules in the Medicare population.
    Cancer. 2023;129:2808-2816.
    PubMed     Abstract available
    
    
    
39. LU S, Guo X, Li Y, Liu H, et al
    Antiprogrammed death ligand 1 therapy failed to reduce the risk of developing brain metastases in patients with extensive-stage small cell lung cancer: A retrospective analysis.
    Cancer. 2023 Sep 8. doi: 10.1002/cncr.35003.
    PubMed     Abstract available
    
    
    
40. TAMMEMAGI MC
    Time to quit using quit time as a lung cancer screening eligibility criterion.
    Cancer. 2023 Sep 1. doi: 10.1002/cncr.34999.
    PubMed    
    
    
    August 2023
41. CARLISLE JW, Leal T
    Advancing immunotherapy in small cell lung cancer.
    Cancer. 2023 Aug 21. doi: 10.1002/cncr.34977.
    PubMed     Abstract available
    
    
    
42. NIERENGARTEN MB
    Overall lung cancer screening rates low.
    Cancer. 2023;129:2440.
    PubMed    
    
    
    
43. SEBASTIAN NT, Webb A, Shilo K, Robb R, et al
    A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy (SBRT).
    Cancer. 2023 Aug 10. doi: 10.1002/cncr.34983.
    PubMed     Abstract available
    
    
    
44. AGARWAL M, Liu A, Almquist D, Langlais BT, et al
    Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
    Cancer. 2023 Aug 7. doi: 10.1002/cncr.34966.
    PubMed     Abstract available
    
    
    
45. BOYLE TA, Bossler AD
    RNA sequencing steps toward the first line.
    Cancer. 2023;129:2294-2296.
    PubMed     Abstract available
    
    
    July 2023
46. BERGER Y, Gadiraju M, Dhiman A, Gilliam K, et al
    Surgical phenotype of patients with peritoneal mesothelioma and a germline mutation.
    Cancer. 2023;129:2152-2160.
    PubMed     Abstract available
    
    
    
47. COLAMONICI M, Khouzam N, Dell C, Auge-Bronersky K, et al
    Promoting lung cancer screening of high-risk patients by primary care providers.
    Cancer. 2023 Jul 14. doi: 10.1002/cncr.34955.
    PubMed     Abstract available
    
    
    June 2023
48. MCCALL NS, Janopaul-Naylor JR, McGinnis HS, Kesarwala AH, et al
    Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
    Cancer. 2023 Jun 24. doi: 10.1002/cncr.34915.
    PubMed     Abstract available
    
    
    
49. LESHEM Y, Dolev Y, Siegelmann-Danieli N, Sharman Moser S, et al
    Association between diabetes mellitus and reduced efficacy of pembrolizumab in non-small cell lung cancer.
    Cancer. 2023 Jun 24. doi: 10.1002/cncr.34918.
    PubMed     Abstract available
    
    
    
50. ZHOU Q, Zhao J, Chang J, Wang H, et al
    Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer.
    Cancer. 2023 Jun 6. doi: 10.1002/cncr.34897.
    PubMed     Abstract available
    
    
    
51. NIERENGARTEN MB
    Risk model-based lung cancer screening.
    Cancer. 2023;129:1628.
    PubMed    
    
    
    
52. NIERENGARTEN MB
    Adherence to evidence-based surgical metrics improves outcomes in lung cancer.
    Cancer. 2023;129:1627.
    PubMed    
    
    
    
53. DESAI A, Reddy NK, Subbiah V
    Top advances of the year: Precision oncology.
    Cancer. 2023;129:1634-1642.
    PubMed     Abstract available
    
    
    
54. GHIAUR G, Valkenburg KC, Esteb C, Ambinder A, et al
    Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4.
    Cancer. 2023;129:1744-1751.
    PubMed     Abstract available
    
    
    May 2023
55. WANG C, Chang Y, Ren J, Wu Z, et al
    Modifiable risk-attributable and age-related burden of lung cancer in China, 1990-2019.
    Cancer. 2023 May 23. doi: 10.1002/cncr.34850.
    PubMed     Abstract available
    
    
    
56. KIDANE B, Gerard IJ, Spicer J, Kim JO, et al
    Stereotactic Ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol.
    Cancer. 2023 May 23. doi: 10.1002/cncr.34880.
    PubMed     Abstract available
    
    
    
57. MAKHARADZE T, Quek RGW, Melkadze T, Gogishvili M, et al
    Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
    Cancer. 2023 May 8. doi: 10.1002/cncr.34687.
    PubMed     Abstract available
    
    
    
58. ALTAN M, Tu J, Milton DR, Yilmaz B, et al
    Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
    Cancer. 2023 May 2. doi: 10.1002/cncr.34820.
    PubMed     Abstract available
    
    
    April 2023
59. JU S, Cui Z, Hong Y, Wang X, et al
    Detection of multiple types of cancer driver mutations using targeted RNA sequencing in nonsmall cell lung cancer.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34804.
    PubMed     Abstract available
    
    
    
60. HERRERA-JUAREZ M, Serrano-Gomez C, Bote-de-Cabo H, Paz-Ares L, et al
    Targeted therapy for lung cancer: Beyond EGFR and ALK.
    Cancer. 2023 Apr 19. doi: 10.1002/cncr.34757.
    PubMed     Abstract available
    
    
    
61. EBERTH JM, Gieske MR, Silvestri GA
    Changing recommendations for lung cancer screening: National Lung Cancer Roundtable member perspectives.
    Cancer. 2023 Apr 14. doi: 10.1002/cncr.34798.
    PubMed    
    
    
    
62. NAKAHAMA K, Izumi M, Yoshimoto N, Fukui M, et al
    Vimentin expression correlates with immune-checkpoint inhibitor efficacy in non-small cell lung cancer.
    Cancer. 2023 Apr 6. doi: 10.1002/cncr.34782.
    PubMed     Abstract available
    
    
    
63. NIERENGARTEN MB
    First person profile: Yi-Long Wu, MD: Dr Wu's research has progressed from improving the survival rates of patients with non-small cell lung cancer and is now focused on ensuring that he and the next generation of researchers can find a cure.: Dr Wu's
    Cancer. 2023;129:978-979.
    PubMed    
    
    
    March 2023
64. WU Y, Verma V, Gay CM, Chen Y, et al
    Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Cancer. 2023 Mar 30. doi: 10.1002/cncr.34755.
    PubMed     Abstract available
    
    
    
65. ERNANI V, Appiah AK, Rodriguez D, Kusne Y, et al
    Lobar versus sublobar resection for atypical lung carcinoid: An analysis from the National Cancer Database.
    Cancer. 2023;129:860-866.
    PubMed     Abstract available
    
    
    
66. BIRONZO P, Cani M, Jacobs F, Napoli VM, et al
    Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy.
    Cancer. 2023 Mar 11. doi: 10.1002/cncr.34731.
    PubMed     Abstract available
    
    
    February 2023
67. VILLARUZ LC, Blumenschein GR Jr, Otterson GA, Leal TA, et al
    Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
    Cancer. 2023 Feb 27. doi: 10.1002/cncr.34683.
    PubMed     Abstract available
    
    
    
68. HE J, Ma P, Zhao D, Shi X, et al
    Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
    Cancer. 2023 Feb 22. doi: 10.1002/cncr.34697.
    PubMed     Abstract available
    
    
    
69. NELSON AT, Harris AK, Watson D, Miniati D, et al
    Type I and Ir pleuropulmonary blastoma (PPB): A report from the International PPB/DICER1 Registry.
    Cancer. 2023;129:600-613.
    PubMed     Abstract available
    
    
    
70. PENG Y, Zhao Q, Liao Z, Ma Y, et al
    Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Cancer. 2023 Feb 7. doi: 10.1002/cncr.34664.
    PubMed     Abstract available
    
    
    December 2022
71. CRONIN KA, Scott S, Firth AU, Sung H, et al
    Annual report to the nation on the status of cancer, part 1: National cancer statistics.
    Cancer. 2022;128:4251-4284.
    PubMed     Abstract available
    
    
    
72. DE MIGUEL-PEREZ D, Russo A, Gunasekaran M, Buemi F, et al
    Baseline extracellular vesicle TGF-beta is a predictive biomarker for response to immune-checkpoint inhibitors and survival in non-small-cell lung cancer.
    Cancer. 2022 Dec 9. doi: 10.1002/cncr.34576.
    PubMed     Abstract available
    
    
    
73. 
    First-line combined therapy improves metastatic non-small cell lung cancer survival regardless of mutational status.
    Cancer. 2022;128:4039.
    PubMed    
    
    
    November 2022
74. LEE Y, Kim HR, Hong MH, Lee KH, et al
    A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-small cell lung cancer with EGFR mutation.
    Cancer. 2022 Nov 30. doi: 10.1002/cncr.34553.
    PubMed     Abstract available
    
    
    
75. SALOUS T, Shukla NA, Althouse SK, Perkins SM, et al
    A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
    Cancer. 2022 Nov 24. doi: 10.1002/cncr.34565.
    PubMed     Abstract available
    
    
    
76. ZHOU T, Zhang Y, Ma Y, Ma W, et al
    Comparison of aprepitant versus desloratadine for EGFR-TKI-induced pruritus: A randomized phase 2 clinical trial.
    Cancer. 2022;128:3969-3976.
    PubMed     Abstract available
    
    
    
77. GOGEBAKAN KC, Lange J, Slatore CG, Etzioni R, et al
    Modeling the impact of novel systemic treatments on lung cancer screening benefits.
    Cancer. 2022 Nov 1. doi: 10.1002/cncr.34527.
    PubMed     Abstract available
    
    
    October 2022
78. GUMUS M, Chen CI, Ivanescu C, Kilickap S, et al
    Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of >/=50%: The EMPOWER-Lung 1 study.
    Cancer. 2022 Oct 29. doi: 10.1002/cncr.34477.
    PubMed     Abstract available
    
    
    
79. 
    Adagrasib shines in a lung cancer trial.
    Cancer. 2022;128:3432-3433.
    PubMed    
    
    
    
80. PATEL AV, Deubler E, Teras LR, Colditz GA, et al
    Key risk factors for the relative and absolute 5-year risk of cancer to enhance cancer screening and prevention.
    Cancer. 2022;128:3502-3515.
    PubMed     Abstract available
    
    
    
81. COLONNA M, Grosclaude P, Bouvier AM, Goungounga J, et al
    Health status of prevalent cancer cases as measured by mortality dynamics (cancer vs. noncancer): Application to five major cancers sites.
    Cancer. 2022;128:3663-3673.
    PubMed     Abstract available
    
    
    September 2022
82. 
    Emphysema linked to increased risk of lung cancer.
    Cancer. 2022;128:3277.
    PubMed    
    
    
    
83. SNYDER RA, Hu CY, DiBrito SR, Chang GJ, et al
    Association of Medicaid expansion with racial disparities in cancer stage at presentation.
    Cancer. 2022;128:3340-3351.
    PubMed     Abstract available
    
    
    
84. PANG LL, Gan JD, Tan JR, Huang YH, et al
    Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
    Cancer. 2022 Sep 7. doi: 10.1002/cncr.34451.
    PubMed     Abstract available
    
    
    
85. O'ROURKE K
    First person profile: Thomas Lynch Jr, MD: Dr Lynch's focus on enabling success makes him an impactful lung cancer specialist, physician-scientist, and physician-executive: Dr Lynch's focus on enabling success makes him an impactful lung cancer specia
    Cancer. 2022;128.
    PubMed    
    
    
    August 2022
86. O'ROURKE K
    Lung cancer screening associated with earlier diagnosis and improved survival.
    Cancer. 2022;128:3011-3012.
    PubMed    
    
    
    
87. MOHINDRA NA, Patel JD
    Top advances in lung cancer, 2021.
    Cancer. 2022 Aug 10. doi: 10.1002/cncr.34406.
    PubMed     Abstract available
    
    
    July 2022
88. BATTAGLIA TA, Gunn CM, Bak SM, Flacks J, et al
    Patient navigation to address sociolegal barriers for patients with cancer: A comparative-effectiveness study.
    Cancer. 2022;128 Suppl 13:2623-2635.
    PubMed     Abstract available
    
    
    June 2022
89. ZABLOTSKA LB, Lane RSD, Randhawa K
    Association between exposures to radon and gamma-ray radiation and histologic type of lung cancer in Eldorado uranium mining and milling workers from Canada.
    Cancer. 2022 Jun 29. doi: 10.1002/cncr.34351.
    PubMed     Abstract available
    
    
    
90. PETRILLO LA, Shimer SE, Zhou AZ, Sommer RK, et al
    Prognostic communication about lung cancer in the precision oncology era: A multiple-perspective qualitative study.
    Cancer. 2022 Jun 22. doi: 10.1002/cncr.34369.
    PubMed     Abstract available
    
    
    
91. CORTELLINI A, Ricciuti B, Borghaei H, Naqash AR, et al
    Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.
    Cancer. 2022 Jun 21. doi: 10.1002/cncr.34348.
    PubMed     Abstract available
    
    
    
92. WARNER ET
    Race, place, and socioeconomic status: A path toward lung cancer early detection.
    Cancer. 2022 Jun 20. doi: 10.1002/cncr.34330.
    PubMed    
    
    
    
93. GUPTA A, Omeogu CH, Islam JY, Joshi AR, et al
    Association of area-level socioeconomic status and non-small cell lung cancer stage by race/ethnicity and health care-level factors: Analysis of the National Cancer Database.
    Cancer. 2022 Jun 20. doi: 10.1002/cncr.34327.
    PubMed     Abstract available
    
    
    
94. JOUNG RH, Nelson H, Mullett TW, Kurtzman SH, et al
    A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
    Cancer. 2022;128:2119-2125.
    PubMed     Abstract available
    
    
    
95. YOO JE, Han K, Shin DW, Jung W, et al
    Effect of smoking reduction, cessation, and resumption on cancer risk: A nationwide cohort study.
    Cancer. 2022;128:2126-2137.
    PubMed     Abstract available
    
    
    May 2022
96. NAITO T, Uchino J, Kojima T, Matano Y, et al
    A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.
    Cancer. 2022;128:2025-2035.
    PubMed     Abstract available
    
    
    
97. O'ROURKE K
    Blood test helps predict who might benefit from lung cancer screening: A recent study examining a test based on a combination of a blood test and a risk prediction model shows that it is more sensitive than current risk prediction criteria.: A recent
    Cancer. 2022;128:1721-1722.
    PubMed    
    
    
    April 2022
98. SHESHADRI A, Goizueta AA, Shannon VR, London D, et al
    Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort study.
    Cancer. 2022 Apr 22. doi: 10.1002/cncr.34229.
    PubMed     Abstract available
    
    
    
99. EZE C, Guggenberger JE, Schmidt-Hegemann NS, Kenndoff S, et al
    Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
    Cancer. 2022 Apr 13. doi: 10.1002/cncr.34201.
    PubMed     Abstract available
    
    
    March 2022
100. O'ROURKE K
     Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.
     Cancer. 2022;128:938.
     PubMed    
     
     
     February 2022
101. WILLIAMS RM, Li T, Luta G, Wang MQ, et al
     Lung cancer screening use and implications of varying eligibility criteria by race and ethnicity: 2019 Behavioral Risk Factor Surveillance System data.
     Cancer. 2022 Feb 24. doi: 10.1002/cncr.34098.
     PubMed     Abstract available
     
     
     
102. PAZ-ARES L, Spigel DR, Chen Y, Jove M, et al
     RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer.
     Cancer. 2022 Feb 23. doi: 10.1002/cncr.34123.
     PubMed     Abstract available
     
     
     
103. LI N, Wang BX, Li J, Shao Y, et al
     Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
     Cancer. 2022;128:708-718.
     PubMed     Abstract available
     
     
     
104. SAHAR L, Douangchai Wills VL, Liu KKA, Fedewa SA, et al
     Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States.
     Cancer. 2022 Feb 15. doi: 10.1002/cncr.33996.
     PubMed     Abstract available
     
     
     
105. LOWENSTEIN LM, Nishi SPE, Lopez-Olivo MA, Crocker LC, et al
     Smoking cessation services and shared decision-making practices among lung cancer screening facilities: A cross-sectional study.
     Cancer. 2022 Feb 14. doi: 10.1002/cncr.34145.
     PubMed     Abstract available
     
     
     
106. WILLIAMS RM, Cordon M, Eyestone E, Smith L, et al
     Improved motivation and readiness to quit shortly after lung cancer screening: Evidence for a teachable moment.
     Cancer. 2022 Feb 10. doi: 10.1002/cncr.34133.
     PubMed     Abstract available
     
     
     January 2022
107. TJOKROWIDJAJA A, Lord SJ, John T, Lewis CR, et al
     Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer.
     Cancer. 2022 Jan 28. doi: 10.1002/cncr.34113.
     PubMed     Abstract available
     
     
     
108. KNEUERTZ PJ, Abdel-Rasoul M, D'Souza DM, Zhao J, et al
     Segmentectomy for clinical stage I non-small cell lung cancer: National benchmarks for nodal staging and outcomes by operative approach.
     Cancer. 2022 Jan 7. doi: 10.1002/cncr.34071.
     PubMed     Abstract available
     
     
     
109. NOONE AM, Pfeiffer RM, Schaubel DE, Dorgan JF, et al
     Life-years lost due to cancer among solid organ transplant recipients in the United States, 1987 to 2014.
     Cancer. 2022;128:150-159.
     PubMed     Abstract available
     
     
     November 2021
110. JAVIER-DESLOGES J, Nelson TJ, Murphy JD, McKay RR, et al
     Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
     Cancer. 2021 Nov 22. doi: 10.1002/cncr.33991.
     PubMed     Abstract available
     
     
     
111. HAY A
     Adjuvant trials suggest changes to non-small cell lung cancer treatment paradigm: Results from clinical trials presented at the 2021 annual meeting of the American Society of Clinical Oncology may point to new ways to improve individualized therapy.
     Cancer. 2021;127:4121-4122.
     PubMed    
     
     
     October 2021
112. KIM H, Kim DW, Kim M, Lee Y, et al
     Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world d
     Cancer. 2021 Oct 27. doi: 10.1002/cncr.33984.
     PubMed     Abstract available
     
     
     September 2021
113. RAMALINGAM SS, Thara E, Awad MM, Dowlati A, et al
     JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
     Cancer. 2021 Sep 3. doi: 10.1002/cncr.33885.
     PubMed     Abstract available
     
     
     August 2021
114. KOBAYASHI M, Kako J, Kajiwara K, Ogata A, et al
     The effects of curative-intent cancer therapy on employment, work ability, and work limitations.
     Cancer. 2021;127:3031-3032.
     PubMed    
     
     
     
115. TEVAARWERK AJ, Kwekkeboom K, Buhr KA, Dennee A, et al
     Reply to The effects of curative-intent cancer therapy on employment, work ability, and work limitations.
     Cancer. 2021;127:3033-3034.
     PubMed    
     
     
     
116. GOULD MK
     Personalized lung cancer screening: Are we ready to ENGAGE?
     Cancer. 2021 Aug 12. doi: 10.1002/cncr.33839.
     PubMed     Abstract available
     
     
     
117. TOUMAZIS I, Alagoz O, Leung A, Plevritis SK, et al
     A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings.
     Cancer. 2021 Aug 12. doi: 10.1002/cncr.33835.
     PubMed     Abstract available
     
     
     
118. PRINTZ C
     First person profile: John D. Minna, MD: This renowned lung cancer researcher continues pioneering treatments, inspiring his colleagues and trainees.
     Cancer. 2021;127:2605-2606.
     PubMed    
     
     
     
119. RECKAMP KL, Behrendt CE, Slavin TP, Gray SW, et al
     Germline mutations and age at onset of lung adenocarcinoma.
     Cancer. 2021;127:2801-2806.
     PubMed     Abstract available
     
     
     July 2021
120. PRINTZ C
     New findings show disparities in lung cancer care and research.
     Cancer. 2021;127:2173.
     PubMed    
     
     
     May 2021
121. HAJDU SI
     Pathfinders in oncology from the time the causal relation between tobacco use and lung cancer was established to publication of the first Cancer Staging Manual by the American Joint Committee on Cancer.
     Cancer. 2021 May 10. doi: 10.1002/cncr.33561.
     PubMed     Abstract available
     
     
     April 2021
122. KHURI FR
     From Cancer to COVID, Boston to Beirut.
     Cancer. 2021;127:1172-1173.
     PubMed    
     
     
     
123. PARK S, Olsen S, Ku BM, Lee MS, et al
     High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program.
     Cancer. 2021 Apr 7. doi: 10.1002/cncr.33571.
     PubMed     Abstract available
     
     
     
124. HU ZI, Ghafoor A, Sengupta M, Hassan R, et al
     Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
     Cancer. 2021;127:1010-1020.
     PubMed     Abstract available
     
     
     February 2021
125. NABI J, Tully KH, Cole AP, Marchese M, et al
     Access denied: The relationship between patient insurance status and access to high-volume hospitals.
     Cancer. 2021;127:577-585.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.